{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:57:24Z","timestamp":1740146244367,"version":"3.37.3"},"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Troms\u00f8 Research Foundation (supported by Trond Mohn)","award":["A32542"],"award-info":[{"award-number":["A32542"]}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["177558\/V30"],"award-info":[{"award-number":["177558\/V30"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["PK01-2009-0541."],"award-info":[{"award-number":["PK01-2009-0541."]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0179700","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T13:43:22Z","timestamp":1499262202000},"page":"e0179700","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy"],"prefix":"10.1371","volume":"12","author":[{"given":"Clemens","family":"Woywod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz X.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Engh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor","family":"Fl\u00e5","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib","volume":"103","author":"C Gambacorti-Passerini","year":"2011","journal-title":"JNCI J Natl Cancer Inst"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1098\/rstb.2014.0364","article-title":"Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke","volume":"370","author":"I Weissman","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2011.10.010","article-title":"Versatility and nuances of the architecture of haematopoiesis \u2013 Implications for the nature of leukaemia","volume":"36","author":"G Brown","year":"2012","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"ref4","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"B Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12185-013-1318-8","article-title":"Stem cell maintenance and disease progression in chronic myeloid leukemia","volume":"98","author":"T Ito","year":"2013","journal-title":"Int J Hematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-014-2556-z","article-title":"A pharmacodynamic model of Bcr\u2013Abl signalling in chronic myeloid leukaemia","volume":"74","author":"RC Jackson","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref8","first-page":"114","article-title":"Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors","volume":"21","author":"ID Ursan","year":"2015","journal-title":"J Manag Care Pharm"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdv110","article-title":"A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia","volume":"26","author":"K Korfi","year":"2015","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"J Cortes","year":"2004","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00257.x","article-title":"Sustained cytogenetic response after discontinuation of imatinib mesilate in a patient with chronic myeloid leukemia","volume":"72","author":"W Ghanima","year":"2004","journal-title":"Eur J Haematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","article-title":"Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases","volume":"76","author":"T Higashi","year":"2004","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"ref13","doi-asserted-by":"crossref","first-page":"s71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"MJ Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"ref14","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"S Merante","year":"2005","journal-title":"Haematologica"},{"issue":"7046","key":"ref15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"F Michor","year":"2005","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"209","author":"P Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"S Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1073\/pnas.1317072111","article-title":"The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia","volume":"111","author":"AL MacLean","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11538-008-9373-7","article-title":"An \u201cage\u201d-structured model of hematopoietic stem cell organization with application to chronic myeloid leukemia","volume":"71","author":"I Roeder","year":"2009","journal-title":"Bull Math Biol"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"I Roeder","year":"2006","journal-title":"Nat Med"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"e1000447","DOI":"10.1371\/journal.pcbi.1000447","article-title":"Stem cell proliferation and quiescence\u2013two sides of the same coin","volume":"5","author":"I Glauche","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s11538-009-9500-0","article-title":"Stability Analysis of a Simplified Yet Complete Model for Chronic Myelogenous Leukemia","volume":"72","author":"M Doumic-Jauffet","year":"2010","journal-title":"Bull Math Biol"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","article-title":"Dynamics and potential impact of the immune response to chronic myelogenous leukemia","volume":"4","author":"PS Kim","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jcp.1030620313","article-title":"The Distribution of Colony-forming Cells Among Spleen Colonies","volume":"62","author":"L Siminovitch","year":"1963","journal-title":"J Cell and Comp Physiol"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","article-title":"Effect of cellular quiescence on the success of targeted CML therapy","volume":"2","author":"NL Komarova","year":"2007","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jtbi.2006.12.012","article-title":"Modeling regulation mechanisms of the immune system","volume":"246","author":"PS Kim","year":"2007","journal-title":"J Theor Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1158\/0008-5472.CAN-15-0611","article-title":"Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib","volume":"75","author":"GD Clapp","year":"2015","journal-title":"Cancer Res"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","article-title":"Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib","volume":"5","author":"J Foo","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3324\/haematol.2013.085977","article-title":"Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib","volume":"99","author":"A Olshen","year":"2014","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e27682","DOI":"10.1371\/journal.pone.0027682","article-title":"Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia","volume":"6","author":"K Leder","year":"2011","journal-title":"PLOS ONE"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mehy.2007.03.040","article-title":"Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation","volume":"70","author":"D Wodarz","year":"2008","journal-title":"Med Hypotheses"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.camwa.2004.07.015","article-title":"Delay Differential Equations with Hill\u2019s Type Growth Rate and Linear Harvesting","volume":"49","author":"L Berezansky","year":"2005","journal-title":"Comput Math Appl"},{"key":"ref33","first-page":"221","article-title":"Recent Trends in Dynamical Systems. vol. 35 of Springer Proceedings in Mathematics & Statistics","author":"T Fl\u00e5","year":"2013"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1002\/mma.3345","article-title":"Bifurcation patterns in generalized models for the dynamics of normal and leukemic stem cells with signaling","volume":"38","author":"T Fl\u00e5","year":"2015","journal-title":"Math Meth Appl Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2006.12.002","article-title":"Resistance to targeted therapy in chronic myelogenous leukemia","volume":"44","author":"A Hochhaus","year":"2007","journal-title":"Semin Hematol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"T Ernst","year":"2008","journal-title":"Haematologica"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"FX Gruber","year":"2005","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","article-title":"A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib","volume":"20","author":"FX Gruber","year":"2006","journal-title":"Leukemia"},{"key":"ref40","unstructured":"Gruber FX. Towards a quantitative understanding of CML resistance. Department of Pharmacology, University of Troms\u00f8; 2009."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/leu.2011.187","article-title":"Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib resistant CML patients","volume":"26","author":"FX Gruber","year":"2012","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4137\/CMO.S6416","article-title":"Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML","volume":"5","author":"MP Shieh","year":"2011","journal-title":"Clin Med Insights Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"16766","DOI":"10.1073\/pnas.1007726107","article-title":"Role of symmetric and asymmetric division of stem cells in developing drug resistance","volume":"107","author":"C Tomasetti","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1371\/journal.pcbi.0030053","article-title":"(A)symmetric stem cell replication and cancer","volume":"3","author":"D Dingli","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.atmosres.2007.07.002","article-title":"Spatial and temporal characteristics of precipitation using an extensive network of ground gauge in the Korean Peninsula","volume":"86","author":"KJ Ha","year":"2007","journal-title":"Atmos Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0771-050X(80)90013-3","article-title":"A family of embedded Runge-Kutta formulae","volume":"6","author":"JR Dormand","year":"1980","journal-title":"J Comp Appl Math"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"MATLAB version 7.11.0. Natick, Ma, USA: The MathWorks Inc.; 2010.","DOI":"10.1016\/S1365-6937(10)70050-2"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1137\/S1064827594276424","article-title":"The MATLAB ODE Suite","volume":"18","author":"LF Shampine","year":"1997","journal-title":"SIAM J Sci Comput"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"M Tang","year":"2011","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/leu.2009.43","article-title":"A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response","volume":"23","author":"MW Drummond","year":"2009","journal-title":"Leukemia"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00277-010-0948-7","article-title":"Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases","volume":"89","author":"L Han","year":"2010","journal-title":"Ann Hematol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2005-03-1240","article-title":"The kinetics of clonal dominance in myeloproliferative disorders","volume":"106","author":"SN Catlin","year":"2005","journal-title":"Blood"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3324\/haematol.2009.015271","article-title":"Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells","volume":"95","author":"T Lenaerts","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtbi.2009.11.022","article-title":"Evolution of resistance to anti-cancer therapy during general dosing schedules","volume":"263","author":"J Foo","year":"2010","journal-title":"J Theor Biol"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"e1000557","DOI":"10.1371\/journal.pcbi.1000557","article-title":"Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies","volume":"5","author":"J Foo","year":"2009","journal-title":"PLoS Comput Biol"},{"issue":"39","key":"ref56","doi-asserted-by":"crossref","first-page":"16616","DOI":"10.1073\/pnas.0908107106","article-title":"A progenitor cell origin of myeloid malignancies","volume":"106","author":"H Haeno","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.tpb.2007.08.003","article-title":"Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer","volume":"72","author":"NL Komarova","year":"2007","journal-title":"Theor Popul Biol"},{"issue":"11","key":"ref58","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-08-1959","article-title":"Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies","volume":"69","author":"NL Komarova","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS One"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: principles of emergence and prevention","volume":"102","author":"NL Komarova","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1-2","key":"ref61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000118786","article-title":"Mathematical modeling of genesis and treatment of chronic myeloid leukemia","volume":"188","author":"M Horn","year":"2008","journal-title":"Cells Tissues Organs"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-007-0241-y","article-title":"Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia\u2013insights from mathematical model analyses","volume":"86","author":"I Roeder","year":"2008","journal-title":"J Mol Med"},{"issue":"4","key":"ref63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603603","article-title":"Leukaemia stem cells: hit or miss?","volume":"96","author":"I Glauche","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"ref64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.moh.0000231418.08031.48","article-title":"Quantitative stem cell biology: computational studies in the hematopoietic system","volume":"13","author":"I Roeder","year":"2006","journal-title":"Curr Opin Hematol"},{"issue":"17","key":"ref65","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2007.15.2421","article-title":"Mathematical models of cancer stem cells","volume":"26","author":"F Michor","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tips.2007.03.003","article-title":"Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia","volume":"28","author":"F Michor","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"ref67","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/stemcells.2006-0638","article-title":"Chronic myeloid leukemia blast crisis arises from progenitors","volume":"25","author":"F Michor","year":"2007","journal-title":"Stem Cells"},{"issue":"9","key":"ref68","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.bjc.6603310","article-title":"Mathematical models of targeted cancer therapy","volume":"95","author":"LH Abbott","year":"2006","journal-title":"Br J Cancer"},{"issue":"12","key":"ref69","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1634\/stemcells.2006-0136","article-title":"Successful therapy must eradicate cancer stem cells","volume":"24","author":"D Dingli","year":"2006","journal-title":"Stem Cells"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s11538-007-9276-z","article-title":"Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models","volume":"70","author":"PS Kim","year":"2008","journal-title":"Bull Math Biol"},{"issue":"7","key":"ref71","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11538-008-9336-z","article-title":"A PDE model for imatinib-treated chronic myelogenous leukemia","volume":"70","author":"PS Kim","year":"2008","journal-title":"Bull Math Biol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s11538-010-9553-0","article-title":"Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia","volume":"73","author":"D Paquin","year":"2010","journal-title":"Bull Math Biol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"HM Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.semcancer.2005.07.002","article-title":"Emergence and prevention of resistance against small molecule inhibitors","volume":"15","author":"D Wodarz","year":"2005","journal-title":"Sem Cancer Biol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"JF Apperley","year":"2007","journal-title":"Lancet Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0179700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T11:31:56Z","timestamp":1569670316000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0179700"}},"subtitle":[],"editor":[{"given":"Natalia L.","family":"Komarova","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0179700","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}